Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess
the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.